Mucoadhesive nanoparticles based on ROS activated gambogic acid prodrug for safe and efficient intravesical instillation chemotherapy of bladder cancer

Xu, Xin; Liu, Kunpeng; Jiao, Binbin; Luo, Kejun; Ren, Jian; Zhang, Guan; Yu, Qingsong; Gan, Zhihua

doi:10.1016/j.jconrel.2020.03.028

Cited by 52 publications

(39 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, they examined the various level of glutathione (GSH) and ROS between normal and cancer cells, the dual responsive NP carrier can selectively deliver the drug into BC cells. As result, the system can significantly prevent the growth of BC cells in an orthotopic superficial BC model without leading to destruction to normal cells [ 137 ].…”

Section: Applications Of Nanomaterials In Treatment Of Bcmentioning

confidence: 99%

Nanotechnology in Bladder Cancer: Diagnosis and Treatment

Barani

Hosseinikhah

Rahdar

et al. 2021

Cancers

View full text Add to dashboard Cite

Bladder cancer (BC) is the second most common cancer of the urinary tract in men and the fourth most common cancer in women, and its incidence rises with age. There are many conventional methods for diagnosis and treatment of BC. There are some current biomarkers and clinical tests for the diagnosis and treatment of BC. For example, radiotherapy combined with chemotherapy and surgical, but residual tumor cells mostly cause tumor recurrence. In addition, chemotherapy after transurethral resection causes high side effects, and lack of selectivity, and low sensitivity in sensing. Therefore, it is essential to improve new procedures for the diagnosis and treatment of BC. Nanotechnology has recently sparked an interest in a variety of areas, including medicine, chemistry, physics, and biology. Nanoparticles (NP) have been used in tumor therapies as appropriate tools for enhancing drug delivery efficacy and enabling therapeutic performance. It is noteworthy, nanomaterial could be reduced the limitation of conventional cancer diagnosis and treatments. Since, the major disadvantages of therapeutic drugs are their insolubility in an aqueous solvent, for instance, paclitaxel (PTX) is one of the important therapeutic agents utilized to treating BC, due to its ability to prevent cancer cell growth. However, its major problem is the poor solubility, which has confirmed to be a challenge when improving stable formulations for BC treatment. In order to reduce this challenge, anti-cancer drugs can be loaded into NPs that can improve water solubility. In our review, we state several nanosystem, which can effective and useful for the diagnosis, treatment of BC. We investigate the function of metal NPs, polymeric NPs, liposomes, and exosomes accompanied therapeutic agents for BC Therapy, and then focused on the potential of nanotechnology to improve conventional approaches in sensing.

show abstract

Section: Applications Of Nanomaterials In Treatment Of Bcmentioning

confidence: 99%

Nanotechnology in Bladder Cancer: Diagnosis and Treatment

Barani

Hosseinikhah

Rahdar

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…At initial diagnosis, almost 75–80% of cases are non-muscle-invasive bladder cancer (NMIBC) and 20–25% patients develop into muscle-invasive disease during their life [ 4 ]. At the present stage, intravesical instillation chemotherapy is the mainstay standard of care for high-risk NMIBC after transurethral resection of the bladder tumor [ 5 ]. However, there are still two formidable challenges hindering the therapeutic effect.…”

Section: Introductionmentioning

confidence: 99%

“…CBD is a potential chemotherapy drug, but how to increase its utilization in the bladder has become a new challenge. To the best of our knowledge, the residence of free drugs inside the bladder is short due to periodic urination [ 5 ]. Given that CBD is highly lipophilic (easy to dissolve in dimethyl sulfoxide (DMSO)) with poor stability (affected by temperature, light, and auto-oxidation [ 22 ]), continuous perfusion is required to maintain high drug concentration; thus, this can result in elevated side effects or occurrence of drug resistance.…”

Section: Introductionmentioning

confidence: 99%

Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment

et al. 2021

View full text Add to dashboard Cite

Cannabidiol (CBD), a primary bioactive phytocannabinoid extracted from hemp, is reported to possess potent anti-tumorigenic activity in multiple cancers. However, the effects of CBD on bladder cancer (BC) and the underlying molecular mechanisms are rarely reported. Here, several experiments proved that CBD promoted BC cells (T24, 5637, and UM-UC-3) death. For example, T24 cells were treated with 12 µM CBD for 48 h, flow cytometry analysis demonstrated that early and late apoptotic cells were accounted for by 49.91%, indicating CBD enhanced cell apoptosis ability. To deeper explore molecular mechanisms, the CBD-treated T24 cell transcriptome libraries were established. KEGG analysis implied that the significantly changed genes were enriched in the PI3K/Akt pathway. qRT-PCR and Western blot assays verified that CBD regulated BC cells growth and migration and induced apoptosis by inactivating the PI3K/Akt pathway. Meanwhile, the developed chitosan to wrap CBD-loaded PLGA nanoparticles can significantly enhance the adhesion of the material to the mouse bladder wall, and the binding efficiency of mucin to chitosan-PLGA nanoparticles reached 97.04% ± 1.90%. In summary, this work demonstrates that CBD may become a novel reliable anticancer drug and the developed intravesical adhesion system is expected to turn into a potential means of BC chemotherapy drug delivery.

show abstract

“…在 2017～2018 年, 该课题组 [39][40][41] [42][43][44][45][46][47][48][49][50][51][52][53] . 早在 2014 年, Hong 等 [46] [54][55][56][57][58][59][60][61] .…”

unclassified

“…早在 2014 年, Hong 等 [46] [54][55][56][57][58][59][60][61] . 2018 年, Jiang 等 [58] 将 CHL 与亲水性聚乙二醇 (polyethylene glycol, PEG)和 4-(羟甲基)苯基硼酸结合图 3 芳基硼酸/酯基 ROS 响应型前药的化学结构 [46][47][48][49][50][51][52][53] Figure 3 Chemical structure of arylboronic acid/ester ROS-responsive prodrugs [46][47][48][49][50][51][52][53] SN38: 7-ethyl-10-hydroxycamptothecin, 5'-DFUR: 5'-deoxy-5-fluorouridine, GEM: gemcitabine, GA: gambogic acid, AMT [58] . Figure 4 (a) Chemical structure of the ROS-responsive CHL prodrug and its self-assembly into prodrug micelles, (b) schematic illustration of intracellular H 2 O 2 -triggered drug release and quinone methide (QM) generation [58] .…”

mentioning

confidence: 99%

Advances in Reactive Oxygen Species Responsive Anti-cancer Prodrugs

Zhang¹,

Chen²,

Wang³

2020

Acta Chim. Sinica

View full text Add to dashboard Cite

Reactive oxygen species (ROS) are categorized as a class of instantaneous intermediate products of oxygen, which are usually produced by a single electron continuous reduction of O 2 . Examples include hydrogen peroxide (H 2 O 2 ), superoxide anion ( 2 O − ), hydroxyl radical (HO•), hypochlorite radical (OCl -) and singlet oxygen ( 1 O 2 ). The endogenous ROS arise from three major resources: mitochondrial electron transport chain (Mito-ETC), endoplasmic reticulum (ER) and NADPH oxidase (NOX). The produced ROS play vital roles in physiological functions including modulation of functions of proteins, regulation of cell signaling, mediation of inflammation, and elimination of pathogens. However, the cumulative ROS level in vivo could elicit oxidative stress, which is implicated in a multitude of diseases including cancer, autoimmune diseases, inflammation, cardiovascular diseases, neurodegenerative diseases. This abnormal biochemical alteration in tumors has inspired researchers to exploit the relatively high levels of ROS for development of ROS-responsive prodrug systems. In recent years, ROS-responsive prodrug systems based on a spectrum of ROS-sensitive linkers have been designed and developed with aim of precision tumor therapy. Herein, in this review, we would like to illustrate ROS-sensitive linkers developed to date including arylboronic acid or ester, alkyl thioether or selenide, thioketal, peroxalate ester, aminoacrylate, thiazolidinone and α-ketoamide, and elucidate the underlying molecular oxidation mechanism. Furthermore, the design of ROS-responsive prodrugs based on these sensitive linkers and their applications in anti-cancer therapy were reviewed. Additionally, the existing problems and the future research perspectives of prodrug systems were also discussed.

show abstract

Mucoadhesive nanoparticles based on ROS activated gambogic acid prodrug for safe and efficient intravesical instillation chemotherapy of bladder cancer

Cited by 52 publications

References 55 publications

Nanotechnology in Bladder Cancer: Diagnosis and Treatment

Nanotechnology in Bladder Cancer: Diagnosis and Treatment

Cannabidiol Effectively Promoted Cell Death in Bladder Cancer and the Improved Intravesical Adhesion Drugs Delivery Strategy Could Be Better Used for Treatment

Advances in Reactive Oxygen Species Responsive Anti-cancer Prodrugs

Contact Info

Product

Resources

About